Roche announces that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of subcutaneous (SC) Ocrevus for its indications in multiple sclerosis (MS).

A final decision on its approval by the European Commission is expected mid-2024. If approved, Ocrevus SC would be the first and only 10-minute injection twice a year for relapsing-remitting (RRMS) and primary-progressive (PPMS) MS in the EU.

The Swiss healthcare group points out that its Ocrevus SC would then represent a new, faster way of administering Ocrevus with an efficacy and safety profile comparable to that of the well-established intravenous infusion.

Copyright (c) 2024 CercleFinance.com. All rights reserved.